Access Bank has restated its commitment to support women and give them the boost they need for their businesses to thrive.

Source: https://leadership.ng/access-bank-restates-commitment-to-women-empowerment/

Alake restated the readiness of the current administration to harness the nation’s mineral resources for national development.

Source: https://thenationonlineng.net/nigerias-mineral-deposits-worth-700b-says-alake/

An amended and restated PPA between Hu Honua and Hawaiian Electric (then HELCO) put the original antitrust lawsuit on hold.

Source: https://www.bigislandvideonews.com/2023/11/17/hu-honua-lawsuit-over-hawaiian-electric-chronic-monopoly-behavior/

Another effective measure is to carry out exit interviews where data protection policies are restated, and leavers are asked to give an assurance that they are not in possession of company devices or information.

Source: https://www.gibraltarfinance.com/articles/business/six-things-you-can-do-now-to-reduce-business-risks-around-your-it-systems

Argus restated a “buy” rating and issued a $165.00 target price on shares of Amazon.com in a research note on Wednesday, September 27th.

Source: https://www.americanbankingnews.com/2023/12/30/fulcrum-capital-llc-has-11-47-million-position-in-amazon-com-inc-nasdaqamzn.html

Bank of America restated a “neutral” rating and set a $173.00 price objective on shares of Apple in a research note on Tuesday.

Source: https://www.americanbankingnews.com/2023/10/27/apple-inc-nasdaqaapl-shares-bought-by-scharf-investments-llc.html

Bank of America restated an “underperform” rating and set a $3.00 target price (down previously from $32.00) on shares of Outset Medical in a research report on Friday, October 13th.

Source: https://www.americanbankingnews.com/2023/11/12/bank-of-montreal-can-purchases-new-position-in-outset-medical-inc-nasdaqom.html

Barrington Research restated an “outperform” rating and set a $243.00 price objective on shares of Kadant in a research report on Friday, July 28th.

Source: https://www.etfdailynews.com/2023/11/03/brown-brothers-harriman-co-sells-46660-shares-of-kadant-inc-nysekai/

Benchmark restated a “buy” rating and issued a $160.00 price objective on shares of Expedia Group in a report on Friday, February 10th.

Source: https://www.etfdailynews.com/2023/04/19/international-assets-investment-management-llc-takes-69000-position-in-expedia-group-inc-nasdaqexpe/

Benchmark restated a “buy” rating and issued a $9.00 target price on shares of Codexis in a research note on Friday, September 1st.

Source: https://www.etfdailynews.com/2023/09/11/codexis-nasdaqcdxs-upgraded-to-hold-by-stocknews-com/

BTIG Research restated a “buy” rating and set a $70.00 price target on shares of Arcus Biosciences in a research note on Wednesday.

Source: https://www.etfdailynews.com/2023/08/26/federated-hermes-inc-buys-2203-shares-of-arcus-biosciences-inc-nysercus-2/

Canaccord Genuity Group restated a “buy” rating and set a $160.00 price objective on shares of PayPal in a research note on Friday, February 10th.

Source: https://www.americanbankingnews.com/2023/04/25/childress-capital-advisors-llc-sells-728-shares-of-paypal-holdings-inc-nasdaqpypl.html

Canaccord Genuity Group restated a “hold” rating and set a $17.00 price target (down from $19.00) on shares of Amryt Pharma in a report on Tuesday.

Source: https://www.etfdailynews.com/2023/01/12/amryt-pharma-nasdaqamyt-sees-strong-trading-volume/

Canaccord Genuity Group restated a “hold” rating on shares of Peloton Interactive in a report on Thursday, November 2nd.

Source: https://www.americanbankingnews.com/2023/12/03/private-advisor-group-llc-acquires-10650-shares-of-peloton-interactive-inc-nasdaqpton.html

Canaccord Genuity Group restated their buy rating on shares of in a research note issued to investors on Tuesday, reports.

Source: https://www.etfdailynews.com/2023/09/30/cleantech-lithium-lonctl-given-buy-rating-at-canaccord-genuity-group/

Cantor Fitzgerald restated an overweight rating and issued a $65.00 price target on shares of Bicycle Therapeutics in a research note on Thursday, September 7th.

Source: https://www.etfdailynews.com/2023/09/16/needham-company-llc-reaffirms-buy-rating-for-bicycle-therapeutics-nasdaqbcyc/

Cantor Fitzgerald restated an “overweight” rating and set a $65.00 price target on shares of Intellia Therapeutics in a report on Tuesday, August 29th.

Source: https://www.dailypolitical.com/2023/09/05/intellia-therapeutics-inc-nasdaqntla-holdings-raised-by-wellington-management-group-llp.html

Cantor Fitzgerald restated an “overweight” rating and set a $75.00 price objective on shares of Pfizer in a research note on Tuesday, September 5th.

Source: https://www.etfdailynews.com/2023/09/10/pfizer-inc-nysepfe-shares-bought-by-avalon-investment-advisory/

Cantor Fitzgerald restated an “overweight” rating and set a $75.00 target price on shares of Pfizer in a research report on Monday, September 18th.

Source: https://www.dailypolitical.com/2023/09/23/grey-street-capital-llc-raises-position-in-pfizer-inc-nysepfe.html

Cantor Fitzgerald restated an “overweight” rating on shares of Bicycle Therapeutics in a research note on Wednesday, September 21st.

Source: https://www.etfdailynews.com/2023/01/07/insider-selling-bicycle-therapeutics-plc-nasdaqbcyc-ceo-sells-6000-shares-of-stock/